25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Adaptimmune Therapeutics Plc
Buy, Hold or Sell?

Let's analyze Adaptimmune together

I guess you are interested in Adaptimmune Therapeutics Plc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Adaptimmune Therapeutics Plc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Adaptimmune Therapeutics Plc

I send you an email if I find something interesting about Adaptimmune Therapeutics Plc.

1. Quick Overview

1.1. Quick analysis of Adaptimmune (30 sec.)










1.2. What can you expect buying and holding a share of Adaptimmune? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.31
Expected worth in 1 year
$0.28
How sure are you?
25.6%

+ What do you gain per year?

Total Gains per Share
$-0.03
Return On Investment
-5.5%

For what price can you sell your share?

Current Price per Share
$0.58
Expected price per share
$0.42 - $0.86
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Adaptimmune (5 min.)




Live pricePrice per Share (EOD)
$0.58
Intrinsic Value Per Share
$-7.44 - $-4.33
Total Value Per Share
$-7.13 - $-4.01

2.2. Growth of Adaptimmune (5 min.)




Is Adaptimmune growing?

Current yearPrevious yearGrowGrow %
How rich?$79.9m$95.1m-$35m-58.5%

How much money is Adaptimmune making?

Current yearPrevious yearGrowGrow %
Making money-$11.2m-$23.8m$12.5m111.9%
Net Profit Margin-5,396.6%-325.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Adaptimmune (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#382 / 944

Most Revenue
#142 / 944

Most Profit
#584 / 944

Most Efficient
#835 / 944
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Adaptimmune?

Welcome investor! Adaptimmune's management wants to use your money to grow the business. In return you get a share of Adaptimmune.

First you should know what it really means to hold a share of Adaptimmune. And how you can make/lose money.

Speculation

The Price per Share of Adaptimmune is $0.5801. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Adaptimmune.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Adaptimmune, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.31. Based on the TTM, the Book Value Change Per Share is $-0.01 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Adaptimmune.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.07-11.9%-0.04-7.7%-0.11-19.8%-0.12-20.8%-0.10-17.5%
Usd Book Value Change Per Share-0.06-10.0%-0.01-1.4%-0.02-4.2%-0.01-2.3%0.011.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.06-10.0%-0.01-1.4%-0.02-4.2%-0.01-2.3%0.011.4%
Usd Price Per Share0.95-1.07-1.06-2.96-5.28-
Price to Earnings Ratio-3.45--1.42--2.58--5.34--20.25-
Price-to-Total Gains Ratio-16.42--10.94-32.02--9.66--149.43-
Price to Book Ratio3.04-6.85-3.01-4.43-6.74-
Price-to-Total Gains Ratio-16.42--10.94-32.02--9.66--149.43-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.5801
Number of shares1723
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.01-0.01
Usd Total Gains Per Share-0.01-0.01
Gains per Quarter (1723 shares)-13.70-22.79
Gains per Year (1723 shares)-54.81-91.16
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-55-650-91-101
20-110-1200-182-192
30-164-1750-273-283
40-219-2300-365-374
50-274-2850-456-465
60-329-3400-547-556
70-384-3950-638-647
80-438-4500-729-738
90-493-5050-820-829
100-548-5600-912-920

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%3.036.00.07.7%3.038.01.07.1%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%10.029.00.025.6%11.031.00.026.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.039.00.0%0.00.042.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%10.029.00.025.6%11.031.00.026.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Adaptimmune Therapeutics Plc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.058-0.008-86%-0.025-57%-0.013-77%0.008-835%
Book Value Per Share--0.3130.233+34%0.372-16%0.685-54%0.743-58%
Current Ratio--3.8483.152+22%3.419+13%5.954-35%6.512-41%
Debt To Asset Ratio--0.7480.804-7%0.698+7%0.533+40%0.374+100%
Debt To Equity Ratio--2.9685.262-44%2.381+25%2.007+48%1.160+156%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--191834210.803213899741.335-10%237322799.760-19%821015322.219-77%1484878490.934-87%
Eps---0.069-0.045-35%-0.115+67%-0.121+75%-0.101+47%
Ev To Ebitda Ratio---3.730-1.276-66%3.106-220%-4.878+31%infnan%
Ev To Sales Ratio--1.17332.505-96%6.239-81%214.727-99%infnan%
Free Cash Flow Per Share---0.214-0.055-74%-0.129-40%-0.083-61%-0.080-63%
Free Cash Flow To Equity Per Share---0.1170.021-651%-0.126+8%0.002-6840%0.012-1062%
Gross Profit Margin--1.0001.0040%1.0000%1.0010%1.0000%
Intrinsic Value_10Y_max---4.326--------
Intrinsic Value_10Y_min---7.443--------
Intrinsic Value_1Y_max---0.318--------
Intrinsic Value_1Y_min---0.395--------
Intrinsic Value_3Y_max---1.043--------
Intrinsic Value_3Y_min---1.498--------
Intrinsic Value_5Y_max---1.875--------
Intrinsic Value_5Y_min---2.933--------
Market Cap148437732.941-64%243191210.803275935741.335-12%272195549.760-11%757330122.219-68%1351872363.312-82%
Net Profit Margin---0.431-53.966+12429%-3.258+656%-30.508+6983%-30.360+6949%
Operating Margin---0.383-58.700+15215%-5.486+1331%-32.643+8417%-29.673+7642%
Operating Ratio--1.35961.211-98%6.130-78%35.489-96%43.731-97%
Pb Ratio1.856-64%3.0406.848-56%3.005+1%4.429-31%6.737-55%
Pe Ratio-2.106+39%-3.451-1.418-59%-2.578-25%-5.335+55%-20.248+487%
Price Per Share0.580-64%0.9501.075-12%1.064-11%2.959-68%5.283-82%
Price To Free Cash Flow Ratio-0.676+39%-1.108-1.539+39%-17.888+1515%-8.266+646%-8.883+702%
Price To Total Gains Ratio-10.023+39%-16.421-10.940-33%32.018-151%-9.658-41%-149.435+810%
Quick Ratio--4.6343.231+43%3.913+18%8.858-48%8.744-47%
Return On Assets---0.055-0.050-11%-0.075+36%-0.086+56%-0.086+55%
Return On Equity---0.220-0.678+208%-0.258+17%-0.301+37%-0.208-6%
Total Gains Per Share---0.058-0.008-86%-0.025-57%-0.013-77%0.008-835%
Usd Book Value--79989000.00060037749.750+33%95133500.000-16%175390799.950-54%190034986.680-58%
Usd Book Value Change Per Share---0.058-0.008-86%-0.025-57%-0.013-77%0.008-835%
Usd Book Value Per Share--0.3130.233+34%0.372-16%0.685-54%0.743-58%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--191834210.803213899741.335-10%237322799.760-19%821015322.219-77%1484878490.934-87%
Usd Eps---0.069-0.045-35%-0.115+67%-0.121+75%-0.101+47%
Usd Free Cash Flow---54886000.000-14009309.500-74%-32910750.000-40%-21274661.900-61%-20464800.974-63%
Usd Free Cash Flow Per Share---0.214-0.055-74%-0.129-40%-0.083-61%-0.080-63%
Usd Free Cash Flow To Equity Per Share---0.1170.021-651%-0.126+8%0.002-6840%0.012-1062%
Usd Market Cap148437732.941-64%243191210.803275935741.335-12%272195549.760-11%757330122.219-68%1351872363.312-82%
Usd Price Per Share0.580-64%0.9501.075-12%1.064-11%2.959-68%5.283-82%
Usd Profit---17617000.000-11233208.000-36%-23801000.000+35%-29694491.600+69%-25578637.003+45%
Usd Revenue--40901000.00043760752.250-7%17769500.000+130%13653800.450+200%10392151.138+294%
Usd Total Gains Per Share---0.058-0.008-86%-0.025-57%-0.013-77%0.008-835%
 EOD+3 -5MRQTTM+14 -24YOY+15 -225Y+12 -2610Y+11 -25

3.3 Fundamental Score

Let's check the fundamental score of Adaptimmune Therapeutics Plc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.106
Price to Book Ratio (EOD)Between0-11.856
Net Profit Margin (MRQ)Greater than0-0.431
Operating Margin (MRQ)Greater than0-0.383
Quick Ratio (MRQ)Greater than14.634
Current Ratio (MRQ)Greater than13.848
Debt to Asset Ratio (MRQ)Less than10.748
Debt to Equity Ratio (MRQ)Less than12.968
Return on Equity (MRQ)Greater than0.15-0.220
Return on Assets (MRQ)Greater than0.05-0.055
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Adaptimmune Therapeutics Plc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5032.516
Ma 20Greater thanMa 500.660
Ma 50Greater thanMa 1000.750
Ma 100Greater thanMa 2000.926
OpenGreater thanClose0.601
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Adaptimmune Therapeutics Plc

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Fundamental data was last updated by Penke on 2024-12-05 11:26:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Adaptimmune earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Adaptimmune to the Biotechnology industry mean.
  • A Net Profit Margin of -43.1% means that $-0.43 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Adaptimmune Therapeutics Plc:

  • The MRQ is -43.1%. The company is making a huge loss. -2
  • The TTM is -5,396.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-43.1%TTM-5,396.6%+5,353.5%
TTM-5,396.6%YOY-325.8%-5,070.8%
TTM-5,396.6%5Y-3,050.8%-2,345.8%
5Y-3,050.8%10Y-3,036.0%-14.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-43.1%-108.6%+65.5%
TTM-5,396.6%-221.4%-5,175.2%
YOY-325.8%-207.4%-118.4%
5Y-3,050.8%-346.2%-2,704.6%
10Y-3,036.0%-470.4%-2,565.6%
4.3.1.2. Return on Assets

Shows how efficient Adaptimmune is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Adaptimmune to the Biotechnology industry mean.
  • -5.5% Return on Assets means that Adaptimmune generated $-0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Adaptimmune Therapeutics Plc:

  • The MRQ is -5.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -5.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.5%TTM-5.0%-0.6%
TTM-5.0%YOY-7.5%+2.6%
TTM-5.0%5Y-8.6%+3.7%
5Y-8.6%10Y-8.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.5%-11.6%+6.1%
TTM-5.0%-12.0%+7.0%
YOY-7.5%-11.2%+3.7%
5Y-8.6%-12.6%+4.0%
10Y-8.6%-14.1%+5.5%
4.3.1.3. Return on Equity

Shows how efficient Adaptimmune is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Adaptimmune to the Biotechnology industry mean.
  • -22.0% Return on Equity means Adaptimmune generated $-0.22 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Adaptimmune Therapeutics Plc:

  • The MRQ is -22.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -67.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-22.0%TTM-67.8%+45.8%
TTM-67.8%YOY-25.8%-42.0%
TTM-67.8%5Y-30.1%-37.7%
5Y-30.1%10Y-20.8%-9.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-22.0%-14.5%-7.5%
TTM-67.8%-16.0%-51.8%
YOY-25.8%-14.6%-11.2%
5Y-30.1%-18.5%-11.6%
10Y-20.8%-19.2%-1.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Adaptimmune Therapeutics Plc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Adaptimmune is operating .

  • Measures how much profit Adaptimmune makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Adaptimmune to the Biotechnology industry mean.
  • An Operating Margin of -38.3% means the company generated $-0.38  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Adaptimmune Therapeutics Plc:

  • The MRQ is -38.3%. The company is operating very inefficient. -2
  • The TTM is -5,870.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-38.3%TTM-5,870.0%+5,831.7%
TTM-5,870.0%YOY-548.6%-5,321.4%
TTM-5,870.0%5Y-3,264.3%-2,605.7%
5Y-3,264.3%10Y-2,967.3%-297.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-38.3%-204.0%+165.7%
TTM-5,870.0%-316.8%-5,553.2%
YOY-548.6%-215.6%-333.0%
5Y-3,264.3%-376.1%-2,888.2%
10Y-2,967.3%-480.3%-2,487.0%
4.3.2.2. Operating Ratio

Measures how efficient Adaptimmune is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.36 means that the operating costs are $1.36 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Adaptimmune Therapeutics Plc:

  • The MRQ is 1.359. The company is inefficient in keeping operating costs low. -1
  • The TTM is 61.211. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.359TTM61.211-59.852
TTM61.211YOY6.130+55.081
TTM61.2115Y35.489+25.722
5Y35.48910Y43.731-8.242
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3592.284-0.925
TTM61.2113.198+58.013
YOY6.1303.247+2.883
5Y35.4894.651+30.838
10Y43.7316.419+37.312
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Adaptimmune Therapeutics Plc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Adaptimmune is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.85 means the company has $3.85 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Adaptimmune Therapeutics Plc:

  • The MRQ is 3.848. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.152. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.848TTM3.152+0.697
TTM3.152YOY3.419-0.267
TTM3.1525Y5.954-2.803
5Y5.95410Y6.512-0.557
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.8483.586+0.262
TTM3.1523.869-0.717
YOY3.4194.644-1.225
5Y5.9545.971-0.017
10Y6.5126.240+0.272
4.4.3.2. Quick Ratio

Measures if Adaptimmune is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Adaptimmune to the Biotechnology industry mean.
  • A Quick Ratio of 4.63 means the company can pay off $4.63 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Adaptimmune Therapeutics Plc:

  • The MRQ is 4.634. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.231. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.634TTM3.231+1.403
TTM3.231YOY3.913-0.683
TTM3.2315Y8.858-5.627
5Y8.85810Y8.744+0.114
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.6343.093+1.541
TTM3.2313.392-0.161
YOY3.9134.304-0.391
5Y8.8585.953+2.905
10Y8.7446.435+2.309
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Adaptimmune Therapeutics Plc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Adaptimmune assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Adaptimmune to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.75 means that Adaptimmune assets are financed with 74.8% credit (debt) and the remaining percentage (100% - 74.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Adaptimmune Therapeutics Plc:

  • The MRQ is 0.748. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.804. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.748TTM0.804-0.056
TTM0.804YOY0.698+0.105
TTM0.8045Y0.533+0.271
5Y0.53310Y0.374+0.159
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7480.346+0.402
TTM0.8040.347+0.457
YOY0.6980.313+0.385
5Y0.5330.365+0.168
10Y0.3740.383-0.009
4.5.4.2. Debt to Equity Ratio

Measures if Adaptimmune is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Adaptimmune to the Biotechnology industry mean.
  • A Debt to Equity ratio of 296.8% means that company has $2.97 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Adaptimmune Therapeutics Plc:

  • The MRQ is 2.968. The company is unable to pay all its debts with equity. -1
  • The TTM is 5.262. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ2.968TTM5.262-2.293
TTM5.262YOY2.381+2.880
TTM5.2625Y2.007+3.254
5Y2.00710Y1.160+0.848
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.9680.393+2.575
TTM5.2620.432+4.830
YOY2.3810.388+1.993
5Y2.0070.455+1.552
10Y1.1600.498+0.662
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Adaptimmune generates.

  • Above 15 is considered overpriced but always compare Adaptimmune to the Biotechnology industry mean.
  • A PE ratio of -3.45 means the investor is paying $-3.45 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Adaptimmune Therapeutics Plc:

  • The EOD is -2.106. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.451. Based on the earnings, the company is expensive. -2
  • The TTM is -1.418. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.106MRQ-3.451+1.345
MRQ-3.451TTM-1.418-2.033
TTM-1.418YOY-2.578+1.160
TTM-1.4185Y-5.335+3.917
5Y-5.33510Y-20.248+14.913
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.106-2.180+0.074
MRQ-3.451-2.507-0.944
TTM-1.418-3.153+1.735
YOY-2.578-3.242+0.664
5Y-5.335-5.992+0.657
10Y-20.248-6.690-13.558
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Adaptimmune Therapeutics Plc:

  • The EOD is -0.676. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.108. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.539. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.676MRQ-1.108+0.432
MRQ-1.108TTM-1.539+0.431
TTM-1.539YOY-17.888+16.349
TTM-1.5395Y-8.266+6.727
5Y-8.26610Y-8.883+0.617
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.676-2.879+2.203
MRQ-1.108-3.276+2.168
TTM-1.539-3.669+2.130
YOY-17.888-4.485-13.403
5Y-8.266-8.015-0.251
10Y-8.883-9.197+0.314
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Adaptimmune is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.04 means the investor is paying $3.04 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Adaptimmune Therapeutics Plc:

  • The EOD is 1.856. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.040. Based on the equity, the company is fair priced.
  • The TTM is 6.848. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD1.856MRQ3.040-1.185
MRQ3.040TTM6.848-3.808
TTM6.848YOY3.005+3.843
TTM6.8485Y4.429+2.419
5Y4.42910Y6.737-2.307
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.8561.964-0.108
MRQ3.0402.056+0.984
TTM6.8482.388+4.460
YOY3.0052.460+0.545
5Y4.4293.697+0.732
10Y6.7374.324+2.413
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Adaptimmune Therapeutics Plc.

4.8.1. Institutions holding Adaptimmune Therapeutics Plc

Institutions are holding 60.266% of the shares of Adaptimmune Therapeutics Plc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Matrix Capital Management Company, LLC14.72611.709837681515-1292670-3.3167
2024-09-30EcoR1 Capital, LLC10.70960.89152740407000
2024-09-30NEA Management Company, LLC6.67480.8841707977800
2024-09-30Baillie Gifford & Co Limited.6.55610.011916775860162665710.7376
2024-09-30Long Focus Capital Management, LLC5.19760.4428132998909534737.7227
2024-09-30Partner Fund Management LP3.90830.538610000787-519444-4.9376
2024-09-30Mpm Asset Management, LLC2.17113.633555546100
2024-09-30MPM Oncology Impact Management LP1.99150.7263509591200
2024-06-30Bank of America Corp1.81850.00044653325-14462-0.3098
2024-09-30Rock Springs Capital Management LP0.94790.075242546800
2024-09-30FMR Inc0.68030.00011740900504192.9825
2024-09-30Morgan Stanley - Brokerage Accounts0.6640.0001169902581736192.7066
2024-09-30Renaissance Technologies Corp0.64740.00241656575-129766-7.2643
2024-09-30JPMorgan Chase & Co0.40860.0001104553382950.7997
2024-09-30Redmile Group, LLC0.27970.040171560700
2024-09-30Millennium Management LLC0.27960.0003715350-64265-8.2432
2024-09-30Marshall Wace Asset Management Ltd0.20420.0006522608377728260.7178
2024-09-30Rathbone Brothers PLC0.16910.002143281800
2024-09-30State Street Corp0.1551039679258911.507
2024-09-30Dafna Capital Management LLC0.13330.076634106400
Total 58.32289.0357149238338+1819217+1.2%

4.9.2. Funds holding Adaptimmune Therapeutics Plc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-08-31Edinburgh Worldwide Ord2.91390.9872745630800
2024-10-31Baillie Gifford Global Discovery A Acc1.29830.42183322172-2746442-45.2565
2024-10-31Baillie Gifford WW Discovery B USD Acc0.6340.38181622277372702.3514
2024-10-31JPM Thematics Genetic Thrps C2 Acc USD0.36710.1274939248-46803-4.7465
2024-04-30Galileo - Biotech Innovation Fund S USD0.29412.263475245800
2024-10-31Mercer Global Small Cap Equity M-5£0.18950.037448478200
2024-11-27SPDR® Portfolio Developed Wld ex-US ETF0.09810.000925108000
2024-11-29Fidelity Enhanced Small Cap ETF0.06950.011417782733421.9154
2024-11-27SPDR® S&P® International Small Cap ETF0.05740.016714689900
2024-09-30Fidelity Nasdaq Composite Index0.05460.000813980100
2024-09-30Top Class Healthcare FI0.02930.487500000
2024-10-31Club Innovation Santé0.01770.06714535100
2024-11-27Invesco NASDAQ Future Gen 200 ETF0.01360.26963480900
2024-09-30Northern Small Cap Core I0.00660.00381689100
2024-06-30NT Quality SCC US Fund - L0.00390.004610076-1710-14.5087
2024-09-30NT Quality Small Cap Core0.00370.00459548-528-5.2402
2024-09-30Palisades AlphaQ Small Growth0.00291.6999732873280
2024-09-30Baillie Gifford US Discovery Instl0.00250.3044638500
2024-10-31Baillie Gifford US Discovery Fund0.00250.2369638500
2024-08-31Guggenheim Active Allocation Fund0.0001027300
Total 6.05937.319615504898-2747543-17.7%

5.3. Insider Transactions

Insiders are holding 0.376% of the shares of Adaptimmune Therapeutics Plc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-06-18Cintia PiccinaSELL245310.93
2024-01-16Adrian RawcliffeSELL93040.79
2024-01-16Elliot NorrySELL22870.79
2024-01-16William C Bertrand JrSELL46810.79
2024-01-12William C Bertrand JrSELL52200.85
2024-01-11Adrian RawcliffeSELL119450.84
2024-01-11Elliot NorrySELL40090.84
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-09-302023-12-312024-03-312024-06-302024-09-30
Income Tax Expense  -687-3,703-4,3903,864-526-1,330-1,8562,687831



5.2. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets317,436
Total Liabilities237,447
Total Stockholder Equity79,989
 As reported
Total Liabilities 237,447
Total Stockholder Equity+ 79,989
Total Assets = 317,436

Assets

Total Assets317,436
Total Current Assets244,214
Long-term Assets73,222
Total Current Assets
Cash And Cash Equivalents 116,741
Short-term Investments 69,349
Net Receivables 38,614
Inventory 1,874
Other Current Assets 17,636
Total Current Assets  (as reported)244,214
Total Current Assets  (calculated)244,214
+/-0
Long-term Assets
Property Plant Equipment 65,290
Intangible Assets 4,283
Long-term Assets Other 3,649
Long-term Assets  (as reported)73,222
Long-term Assets  (calculated)73,222
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities63,457
Long-term Liabilities173,990
Total Stockholder Equity79,989
Total Current Liabilities
Short-term Debt 4,175
Accounts payable 9,069
Other Current Liabilities 31,504
Total Current Liabilities  (as reported)63,457
Total Current Liabilities  (calculated)44,748
+/- 18,709
Long-term Liabilities
Long term Debt 49,865
Capital Lease Obligations 24,630
Long-term Liabilities Other 4,939
Long-term Liabilities  (as reported)173,990
Long-term Liabilities  (calculated)79,434
+/- 94,556
Total Stockholder Equity
Common Stock2,084
Retained Earnings -1,019,772
Accumulated Other Comprehensive Income -5,136
Other Stockholders Equity 1,102,813
Total Stockholder Equity (as reported)79,989
Total Stockholder Equity (calculated)79,989
+/-0
Other
Capital Stock2,084
Cash and Short Term Investments 186,090
Common Stock Shares Outstanding 255,769
Current Deferred Revenue18,709
Liabilities and Stockholders Equity 317,436
Net Debt -92,111
Net Invested Capital 129,854
Net Working Capital 180,757
Property Plant and Equipment Gross 138,230
Short Long Term Debt Total 24,630



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302013-06-30
> Total Assets 
1,812
55,518
0
137,715
0
300,300
297,310
290,300
261,560
239,560
222,644
234,515
265,980
284,279
301,377
281,147
247,068
211,299
309,625
276,736
270,440
239,521
208,251
181,543
285,241
512,201
479,022
451,142
411,581
389,793
353,528
469,545
419,799
388,270
332,202
328,916
288,081
342,984
296,638
282,616
258,010
321,702
317,436
317,436321,702258,010282,616296,638342,984288,081328,916332,202388,270419,799469,545353,528389,793411,581451,142479,022512,201285,241181,543208,251239,521270,440276,736309,625211,299247,068281,147301,377284,279265,980234,515222,644239,560261,560290,300297,310300,3000137,715055,5181,812
   > Total Current Assets 
0
54,088
0
134,868
0
294,700
282,556
265,200
238,561
218,182
199,544
198,751
222,932
237,744
253,904
230,183
195,663
161,654
261,605
231,095
200,301
175,133
146,970
120,489
227,761
458,087
426,733
398,152
359,293
337,344
300,450
415,458
359,461
321,165
264,139
255,370
213,748
261,771
219,368
207,552
186,903
253,770
244,214
244,214253,770186,903207,552219,368261,771213,748255,370264,139321,165359,461415,458300,450337,344359,293398,152426,733458,087227,761120,489146,970175,133200,301231,095261,605161,654195,663230,183253,904237,744222,932198,751199,544218,182238,561265,200282,556294,7000134,868054,0880
       Cash And Cash Equivalents 
248
51,274
0
101,434
0
228,800
217,076
193,100
163,766
150,894
140,440
158,779
170,559
121,998
145,326
84,043
53,375
42,312
153,081
68,379
49,917
34,574
39,409
50,412
86,429
122,359
78,466
56,882
32,432
50,453
42,918
149,948
89,539
97,811
79,001
108,033
119,866
76,969
90,059
143,991
140,670
211,810
116,741
116,741211,810140,670143,99190,05976,969119,866108,03379,00197,81189,539149,94842,91850,45332,43256,88278,466122,35986,42950,41239,40934,57449,91768,379153,08142,31253,37584,043145,326121,998170,559158,779140,440150,894163,766193,100217,076228,8000101,434051,274248
       Short-term Investments 
0
55,000
0
24,807
0
55,200
54,838
54,300
62,337
55,031
47,064
22,694
33,114
98,023
86,532
124,218
108,459
86,716
84,652
136,755
118,241
98,832
63,451
39,130
110,000
296,629
321,442
311,335
285,512
234,917
197,202
219,632
214,679
160,278
120,669
96,572
45,688
127,738
71,669
2,947
2,982
2,979
69,349
69,3492,9792,9822,94771,669127,73845,68896,572120,669160,278214,679219,632197,202234,917285,512311,335321,442296,629110,00039,13063,45198,832118,241136,75584,65286,716108,459124,21886,53298,02333,11422,69447,06455,03162,33754,30054,83855,200024,807055,0000
       Net Receivables 
0
1,889
0
8,628
0
10,600
10,508
17,500
1
1,000
1,000
1,480
107
1,406
4,063
206
21,188
18,605
13,849
192
22,488
30,773
31,726
20,671
23,004
26,746
13,921
139
31,141
39,913
45,087
752
42,888
49,425
53,534
7,435
1,715
2,970
789
46,919
28,892
23,765
38,614
38,61423,76528,89246,9197892,9701,7157,43553,53449,42542,88875245,08739,91331,14113913,92126,74623,00420,67131,72630,77322,48819213,84918,60521,1882064,0631,4061071,4801,0001,000117,50010,50810,60008,62801,8890
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
1,192
0
0
0
3,760
3,843
2,993
1,190
1,087
862
1,755
1,522
1,459
952
1,521
2,488
2,086
1,576
1,591
1,285
746
10,077
1,327
8,052
1,279
1,310
1,334
1,290
1,329
0
0
1,874
1,874001,3291,2901,3341,3101,2798,0521,32710,0777461,2851,5911,5762,0862,4881,5219521,4591,5221,7558621,0871,1902,9933,8433,7600001,19200000000000
   > Long-term Assets 
0
1,431
0
2,847
0
5,600
14,754
25,100
22,999
21,378
23,100
35,764
43,048
46,535
47,473
50,964
51,405
49,645
48,020
45,641
70,139
64,388
61,281
61,054
57,480
54,114
52,289
52,990
52,288
52,449
53,078
54,087
60,338
67,105
68,063
73,546
74,333
81,213
77,270
75,064
71,107
67,932
73,222
73,22267,93271,10775,06477,27081,21374,33373,54668,06367,10560,33854,08753,07852,44952,28852,99052,28954,11457,48061,05461,28164,38870,13945,64148,02049,64551,40550,96447,47346,53543,04835,76423,10021,37822,99925,10014,7545,60002,84701,4310
       Property Plant Equipment 
209
1,431
0
2,847
0
5,400
11,575
13,155
13,845
13,444
15,086
27,899
35,092
38,922
39,771
40,679
41,235
39,472
38,137
36,118
60,165
55,229
52,204
51,857
48,172
45,912
45,718
46,658
46,065
46,435
50,170
51,369
57,834
64,780
65,783
71,535
72,312
77,519
73,873
71,708
67,725
64,070
65,290
65,29064,07067,72571,70873,87377,51972,31271,53565,78364,78057,83451,36950,17046,43546,06546,65845,71845,91248,17251,85752,20455,22960,16536,11838,13739,47241,23540,67939,77138,92235,09227,89915,08613,44413,84513,15511,5755,40002,84701,431209
       Intangible Assets 
0
0
0
0
0
200
179
2,800
1,140
1,010
1,127
1,268
1,310
1,431
1,374
1,337
1,238
1,196
1,515
1,473
1,529
2,066
2,274
2,198
2,366
2,134
1,970
1,730
1,619
1,382
1,191
1,000
788
612
568
442
443
463
384
330
524
996
4,283
4,2839965243303844634434425686127881,0001,1911,3821,6191,7301,9702,1342,3662,1982,2742,0661,5291,4731,5151,1961,2381,3371,3741,4311,3101,2681,1271,0101,1402,80017920000000
       Other Assets 
0
0
0
0
0
178
3,171
11,949
9,154
7,934
8,014
7,865
7,956
7,613
7,702
10,285
8,932
8,977
8,368
8,050
8,445
7,093
6,803
6,999
6,942
6,068
4,601
4,602
4,604
4,632
1,717
1,718
1,716
1,713
1,712
1,569
0
3,231
3,013
0
0
0
0
00003,0133,23101,5691,7121,7131,7161,7181,7174,6324,6044,6024,6016,0686,9426,9996,8037,0938,4458,0508,3688,9778,93210,2857,7027,6137,9567,8658,0147,9349,15411,9493,17117800000
> Total Liabilities 
3,968
53,108
0
45,850
0
41,000
46,632
54,200
42,614
42,569
42,640
68,373
57,654
54,784
72,392
78,163
55,806
46,197
33,470
29,851
50,785
52,530
60,568
57,905
99,204
104,616
102,816
109,915
102,424
111,854
112,545
263,585
256,654
246,353
218,865
247,038
204,205
216,333
208,509
243,103
233,635
225,428
237,447
237,447225,428233,635243,103208,509216,333204,205247,038218,865246,353256,654263,585112,545111,854102,424109,915102,816104,61699,20457,90560,56852,53050,78529,85133,47046,19755,80678,16372,39254,78457,65468,37342,64042,56942,61454,20046,63241,000045,850053,1083,968
   > Total Current Liabilities 
3,968
53,108
0
45,850
0
26,700
33,177
27,700
19,838
20,137
22,661
40,270
31,912
30,253
68,572
74,314
51,922
42,310
29,566
24,437
23,435
28,293
37,401
34,341
29,816
38,559
34,899
39,073
31,307
41,416
41,137
62,541
66,151
73,632
66,080
64,501
63,631
76,125
75,146
72,788
66,411
82,073
63,457
63,45782,07366,41172,78875,14676,12563,63164,50166,08073,63266,15162,54141,13741,41631,30739,07334,89938,55929,81634,34137,40128,29323,43524,43729,56642,31051,92274,31468,57230,25331,91240,27022,66120,13719,83827,70033,17726,700045,850053,1083,968
       Short-term Debt 
0
0
0
0
0
0
0
0
5,270
7,594
9,418
16,448
13,828
0
0
0
0
0
0
0
2,217
2,338
2,337
2,493
2,590
2,493
2,619
2,773
2,845
2,922
2,267
2,320
2,735
2,557
2,474
2,728
2,842
4,752
5,081
10,768
5,250
10,586
4,175
4,17510,5865,25010,7685,0814,7522,8422,7282,4742,5572,7352,3202,2672,9222,8452,7732,6192,4932,5902,4932,3372,3382,217000000013,82816,4489,4187,5945,27000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,217
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000002,21700000000000000000000
       Accounts payable 
1,916
1,013
0
45,850
0
26,700
4,667
7,840
2,440
2,474
3,193
11,350
5,177
4,577
2,489
8,378
5,051
4,131
3,907
4,083
5,391
4,344
5,535
6,357
7,066
8,766
4,030
6,389
4,116
6,977
4,784
8,113
7,017
15,991
6,905
4,753
5,187
14,713
13,922
8,128
6,587
7,513
9,069
9,0697,5136,5878,12813,92214,7135,1874,7536,90515,9917,0178,1134,7846,9774,1166,3894,0308,7667,0666,3575,5354,3445,3914,0833,9074,1315,0518,3782,4894,5775,17711,3503,1932,4742,4407,8404,66726,700045,85001,0131,916
       Other Current Liabilities 
514
52,095
0
0
0
24,744
4,390
19,897
51
129
536
1,080
1,282
13,372
23,491
27,201
19,650
21,457
24,314
20,354
15,827
18,595
26,846
23,363
18,502
23,836
24,615
27,079
22,263
26,606
27,984
29,909
31,627
32,616
36,079
33,500
33,298
25,242
26,831
23,521
23,050
25,557
31,504
31,50425,55723,05023,52126,83125,24233,29833,50036,07932,61631,62729,90927,98426,60622,26327,07924,61523,83618,50223,36326,84618,59515,82720,35424,31421,45719,65027,20123,49113,3721,2821,0805361295119,8974,39024,74400052,095514
   > Long-term Liabilities 
0
1,013
0
45,850
0
14,300
13,455
26,500
22,776
22,432
19,979
28,103
25,742
24,531
3,820
3,849
3,884
3,887
3,904
5,414
27,350
24,237
23,167
23,564
69,388
66,057
67,917
70,842
71,117
70,438
71,408
201,044
190,503
172,721
152,785
182,537
140,574
140,208
133,363
170,315
167,224
143,355
173,990
173,990143,355167,224170,315133,363140,208140,574182,537152,785172,721190,503201,04471,40870,43871,11770,84267,91766,05769,38823,56423,16724,23727,3505,4143,9043,8873,8843,8493,82024,53125,74228,10319,97922,43222,77626,50013,45514,300045,85001,0130
       Other Liabilities 
0
0
0
0
0
14,311
13,422
26,503
22,776
22,432
19,335
28,103
25,742
24,531
3,820
3,849
3,884
3,887
3,904
5,414
571
571
568
598
47,559
45,243
46,827
49,904
51,220
50,715
47,704
177,896
167,283
151,086
132,859
162,188
0
118,618
112,843
0
0
0
0
0000112,843118,6180162,188132,859151,086167,283177,89647,70450,71551,22049,90446,82745,24347,5595985685715715,4143,9043,8873,8843,8493,82024,53125,74228,10319,33522,43222,77626,50313,42214,31100000
       Deferred Long Term Liability 
0
0
0
0
0
14,885
0
24,962
22,776
22,432
19,335
24,962
22,394
20,754
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000020,75422,39424,96219,33522,43222,77624,962014,88500000
> Total Stockholder Equity
0
2,410
0
91,864
0
259,300
250,678
236,187
218,946
196,991
180,004
166,142
208,326
229,495
228,985
202,984
191,262
165,102
276,155
246,885
219,655
186,991
147,683
123,638
186,037
407,585
376,206
341,227
309,157
277,939
240,983
205,960
163,145
141,917
113,337
81,878
83,876
126,651
88,129
39,513
24,375
96,274
79,989
79,98996,27424,37539,51388,129126,65183,87681,878113,337141,917163,145205,960240,983277,939309,157341,227376,206407,585186,037123,638147,683186,991219,655246,885276,155165,102191,262202,984228,985229,495208,326166,142180,004196,991218,946236,187250,678259,300091,86402,4100
   Retained Earnings -1,019,772-1,002,155-1,071,676-1,023,173-975,256-929,655-908,266-909,302-880,052-838,631-794,111-743,846-704,988-662,587-623,519-585,756-549,143-513,711-483,831-455,664-426,300-386,998-345,911-318,499-282,326-287,568-244,063-231,630-204,367-203,489-183,274-161,492-146,078-127,584-105,489-51,400-44,939-47,1000-34,0840-32,2630
   Accumulated Other Comprehensive Income 
0
187
0
182
0
253,000
122,079
237,400
-10,684
-13,011
-13,788
-14,249
-14,366
-16,854
-20,055
-21,641
-27,136
-14,419
-12,813
-9,763
-13,096
-8,199
-10,025
-7,264
-9,590
-8,805
-8,494
-10,048
-10,224
-10,385
-10,098
-11,142
-9,313
-1,043
6,683
-875
-1,785
-3,092
102
-3,748
-2,720
-3,412
-5,136
-5,136-3,412-2,720-3,748102-3,092-1,785-8756,683-1,043-9,313-11,142-10,098-10,385-10,224-10,048-8,494-8,805-9,590-7,264-10,025-8,199-13,096-9,763-12,813-14,419-27,136-21,641-20,055-16,854-14,366-14,249-13,788-13,011-10,684237,400122,079253,000018201870
   Capital Surplus 
0
0
0
0
0
0
0
0
334,437
336,904
339,188
341,200
405,165
448,985
452,553
455,401
461,603
466,229
570,355
574,208
577,722
581,245
583,065
585,623
678,319
928,777
932,518
935,706
941,569
949,575
954,732
959,611
965,227
980,204
985,312
0
0
0
0
0
0
0
0
00000000985,312980,204965,227959,611954,732949,575941,569935,706932,518928,777678,319585,623583,065581,245577,722574,208570,355466,229461,603455,401452,553448,985405,165341,200339,188336,904334,43700000000
   Treasury Stock0000000000000000000000000000000000000000000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.